First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
Pivotal data set the stage for slightly delayed US accelerated approval filing.
Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
So far the data, with a Car-T Legend licensed to Novartis, lag antibody approaches.
But first it will need to identify the optimal dose in first-line small-cell lung cancer.
But results come from a curated dataset, with no in-trial comparator.
The latest projects newly into human trials include BNT3212.